BioSpace News Archive

Avivagen Inc. (TSXV:VIV) (“Avivagen”) is pleased to announce that it presented at the 5th Annual Torrey Hills Capital Emerging Growth Conference on November 21, 2019.

Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Neovasc Reducer™ (the “Reducer”) was featured during a program hosted in Coburg on Wednesday, November 20, 2019.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, is hosting an R&D Day in New York City today

Yesterday, the New Orleans Business Alliance and two of the region’s largest healthcare organizations, Blue Cross and Blue Shield of Louisiana and Ochsner Health System, announced they are looking for new partners to address critical behavioral health needs for their customers.

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the presentation of interim data from Part B of the ongoing Phase 1/2a study of VBI-1901, its cancer vaccine immunotherapeutic candidate, in recurrent glioblastoma (GBM) patients in a poster presentation at the 24th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO).

Horizon Therapeutics plc (Nasdaq: HZNP) announced today the opening of its new office in South San Francisco, located at 2 Tower Place, 12th floor

ValueHealth, LLC a privately held, nationally trusted digital and surgical healthcare partner, is pleased to announce the hiring of Elizabeth Jaekle as Mid-Atlantic Regional President

The nation’s leading hospital and healthcare experts convened in Washington, D.C., Nov. 17-19, 2019, for the seventh annual U.S. News & World Report Healthcare of Tomorrow summit.

GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc., the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer, will present at two upcoming conferences:.